PDS Biotechnology Corp (NAS:PDSB)

$ 3.51 -0.32 (-8.36%) Market Cap: 128.74 Mil Enterprise Value: 107.77 Mil PE Ratio: 0 PB Ratio: 4.85 GF Score: 35/100

Q4 2023 PDS Biotechnology Corp Earnings Call Transcript
Mar 27, 2024

$3.85 (-14.06%)

Earnings
Q3 2023 PDS Biotechnology Corp Earnings Call Transcript
Nov 14, 2023

$6.23 (+18.55%)

Earnings
PDS Biotechnology Corp To Host Key Opinion Leader Roundtable Transcript
Oct 03, 2023
PDS Biotechnology Corp at Cantor Fitzgerald Global Healthcare Conference Transcript
Sep 26, 2023
Q2 2023 PDS Biotechnology Corp Earnings Call Transcript
Aug 14, 2023

$5.33 (+9.90%)

Earnings
PDS Biotechnology Corp To Host Post ASCO Call Transcript
Jun 06, 2023
Q1 2023 PDS Biotechnology Corp Earnings Call Transcript
May 15, 2023

$6.93 (+7.44%)

Earnings
PDS Biotechnology Corp To Host Key Opinion Leader Call Transcript
Apr 21, 2023
Q4 2022 PDS Biotechnology Corp Earnings Call Transcript
Mar 28, 2023

$5.85 (+2.99%)

Earnings
PDS Biotechnology Corp at Noble Capital Markets Takeaway Series on Channelchek- J.P. Morgan Healthcare Conference Transcript
Jan 26, 2023
PDS Biotechnology Corp Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine Transcript
Jan 03, 2023
Q3 2022 PDS Biotechnology Corp Earnings Call Transcript
Nov 14, 2022

$7.06 (+26.07%)

Earnings
PDS Biotechnology Corp Head And Neck Cancer KOL Roundtable Transcript
Oct 26, 2022
PDS Biotechnology Corp Update Call Transcript
Aug 25, 2022
Q2 2022 PDS Biotechnology Corp Earnings Call Transcript
Aug 08, 2022

$5.19 (-2.26%)

Earnings
PDS Biotechnology Corp Post ASCO Call Transcript
Jun 07, 2022
Q1 2022 PDS Biotechnology Corp Earnings Call Transcript
May 11, 2022

$3.76 (-15.88%)

Earnings
Q4 2021 PDS Biotechnology Corp Earnings Call Transcript
Mar 31, 2022

$6.19 (-1.59%)

Earnings
PDS Biotechnology Corp Extraordinary Shareholders Meeting Transcript
Jan 19, 2022
Q3 2021 PDS Biotechnology Corp Earnings Call Transcript
Nov 10, 2021

$10.2 (-4.40%)

Earnings
Q2 2021 PDS Biotechnology Corp Earnings Call Transcript
Aug 12, 2021

$10.89 (+2.83%)

Earnings
PDS Biotechnology Corp Oncology R&D Day Transcript
Jun 16, 2021
PDS Biotechnology Post-ASCO Conference Call - Corporate Analyst Meeting Transcript
Jun 08, 2021
Q1 2021 PDS Biotechnology Corp Earnings Call Transcript
May 13, 2021

$4.48 (+1.82%)

Earnings
Q2 2020 PDS Biotechnology Corp Earnings Call Transcript
Aug 13, 2020

$2.94

Earnings

PDS Biotechnology Corp at Cantor Fitzgerald Global Healthcare Conference Transcript

Sep 26, 2023 / 06:45PM GMT

Release Date Price: $5.22 (+2.15%)

Transcript

Wayne Wu

Cantor Fitzgerald - Analyst

So good afternoon. My name is Wayne Wu and I am the associate on Louise Chen's Large Cap Pharma, BioPharma & Biotech team here at Cantor. Thank you so much for joining us today with our panel presentation with PDS Biotechnology as well as Immutep. We're thrilled to have Frank as well as Marc to give us their wonderful presentations. So let's start with Frank. Thank you.

Frank Bedu;Addo

PDS Biotechnology Corporation - CEO

Thank you very much for the introduction. Let's see. How do I move this forward? Okay. Okay. So I'm just before I start, I'd just like please to advise everyone to get comfortable and be familiar with the risk factors associated with PDS and as filed with the SEC.

So who is PDS Biotechnology? We are a mid to late clinical stage biotech company developing immunotherapies that train and activate the immune system to specifically target cancer. We are developing targeted immunotherapies based on the company's proprietary, Versamune T-cell activating technology platform.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.